Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite
Not a traditional drug phase: A dietary supplement powder for women for Polycystic Ovarian Syndrome (PCOS)
The rationale for this study is to observe the impact of a consumer-grade commercially available product called Milamend Hormone Balance on quality of life and hormonal health in women with self-reported symptoms associated with Polycystic Ovarian Syndrome (PCOS). Additionally, the study aims to observe the impact of the product on menstrual cycle structure and associated symptoms, on reproductive and metabolic markers, on body image concerns, anxiety and general well-being.
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are A dietary supplement powder for women, or Placebo. The registry lists allocation as randomized. The rationale for this study is to observe the impact of a consumer-grade commercially available product called Milamend Hormone Balance on quality of life and hormonal health in women with self-reported symptoms associated with Polycystic Ovarian Syndrome (PCOS).
They plan to enroll about 225 people at Los Angeles. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Impact of Milamend on Quality of Life and Hormonal Health in Women With Self-Reported Symptoms Associated With Polycystic Ovary Syndrome (PCOS)
Interventions: A dietary supplement powder for women, Placebo
Primary outcome (registry wording): Quality of Life Impact
Who it is for (from inclusion criteria)
Ages 18 Years to 40 Years
Women only
Females between 18-40 years old, inclusive
Known diagnosis of Polycystic Ovarian Syndrome (PCOS) OR likely have PCOS as defined by presence of:
Oligomenorrhea (\<9 menstrual cycles in the past year)
Signs of hyperandrogenism (hirsutism, acne, female-pattern hair loss)
Has recorded menstrual cycle duration of at least 3 menstrual cycles in the past year
Owns or is willing to purchase a personal digital weight scale for monthly weight measurement
In good general health at the time of screening (Investigator discretion)
Who the registry excludes
Any potential participants who:
Do not have a personal smartphone, internet access, or unwilling to download Chloe
Rates the impact of PCOS on their overall quality of life as "Rarely/Seldom" or "Not at all"
Average cycle length of last 3 cycles is \>50 days
Concomitant Therapies:
Use of hormonal contraceptives within the last 6 months
Use of a Co-Q10 supplement within the last 6 months
This study is a double blind, dummy treatment (placebo) controlled, randomly assigned trial of study subjects with PCOS and low vitamin D to 2 groups- dummy treatment (placebo) and vitamin D replacement. Participants and investigators will be blinded to treatment modality until the end of the trial period
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.
The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race/ethnicity, body-mass index (BMI), and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07764328?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07764328?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.